Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Dementia01:30

Dementia

498
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
498
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

547
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
547
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Seizures: Classification01:13

Seizures: Classification

1.3K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reversible limbic encephalitis with antibodies against the membranes of neurones of the hippocampus.

BMJ case reports·2025
Same author

Symptomatology and Neuropathology of patients presenting with focal cortical signs.

Neuropathology : official journal of the Japanese Society of Neuropathology·2022
Same author

Late-onset autosomal recessive cerebellar ataxia and neuropathy with a novel splicing mutation in the <i>ATM</i> gene.

Journal of integrative neuroscience·2020
Same author

Histopathologic Analysis of Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL): A Report of a New Genetically Confirmed Case and Comparison to 2 Previous Cases.

Journal of neuropathology and experimental neurology·2016
Same author

Subacute autonomic and sensory neuropathy closely related to cytomegalovirus infection preceded by frequent syncopal attacks.

Rinsho shinkeigaku = Clinical neurology·2016
Same author

ALS patients with ability to communicate after long-term mechanical ventilation have confined degeneration to the motor neuron system.

Journal of the neurological sciences·2016

Related Experiment Video

Updated: Jan 10, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.1K

[Frontotemporal lobar degeneration (FTLD) concept and classification update].

Imaharu Nakano1

  • 1Division of Neurology, Department of Medicine, Jichi Medical University.

Rinsho Shinkeigaku = Clinical Neurology
|January 27, 2012
PubMed
Summary
This summary is machine-generated.

Frontotemporal lobar degeneration (FTLD) is now classified by inclusion body proteins, moving beyond its neuroanatomical definition. This molecular neuropathology approach clarifies FTLD heterogeneity into FTLD-tau, FTLD-TDP, and FTLD-FUS subgroups.

More Related Videos

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.9K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.5K

Related Experiment Videos

Last Updated: Jan 10, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.1K
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.9K
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
08:29

Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans

Published on: December 18, 2016

14.5K

Area of Science:

  • Neuroscience
  • Neuropathology
  • Molecular Biology

Context:

  • Frontotemporal lobar degeneration (FTLD) was historically defined by frontal and temporal lobe degeneration, leading to diagnostic ambiguity.
  • Pick disease, a prototype of FTLD, exemplified this nosological confusion.
  • Previous classifications lacked precision due to heterogeneous underlying pathologies.

Purpose:

  • To reclassify Frontotemporal Lobar Degeneration (FTLD) based on molecular neuropathology.
  • To resolve the nosological confusion surrounding FTLD and its subtypes.
  • To establish a new, concise nomenclature and classification system for FTLD.

Summary:

  • Molecular neuropathology has clarified FTLD by identifying protein constituents in inclusion bodies.
  • FTLD is now classified into three main subgroups: FTLD-tau, FTLD-TDP (including ALS with dementia), and FTLD-FUS.
  • TDP-43 and FUS/TLS are key proteins identified in FTLD subtypes, with further protein discoveries anticipated.

Impact:

  • Provides a precise classification for heterogeneous FTLD conditions.
  • Facilitates accurate diagnosis and understanding of FTLD spectrum disorders.
  • Enables targeted research into the molecular mechanisms of FTLD subtypes.